Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival.

ABSTRACT: Stage III non-small cell lung cancer (NSCLC) includes a highly heterogeneous group of patients with differences in the extent and localization of disease. Many aspects of stage III disease are controversial. The data supporting treatment approaches are often subject to a number of limitations, due to the heterogeneous patient populations involved in the trials. Furthermore, the definition of stage III disease has changed over time, and early studies were frequently inadequately powered to detect small differences in therapeutic outcome, were not randomized, or had a limited follow-up times. Major improvements in therapy, including the use of more active chemotherapy agents and refinements in radiation and surgical techniques, also limit the interpretation of earlier clinical trials. Lastly

SUBMITTER: Casal-Mourino A 

PROVIDER: S-EPMC7867742 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature